Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
LIVONIA, Mich., June 01, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.
| LD Micro Invitational | |||
| Date: | Tuesday, June 6th | ||
| Time: | 4:00 pm Pacific Time | ||
| Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
| Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8th | ||
| Time: | 4:00pm Eastern Time | ||
| Presenter: | Lee Golden, MD, Chief Medical Officer | ||
| Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
| Webcast: | http://wsw.com/webcast/jeff105/gemp | ||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
